Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206297 · ClinicalTrials.gov registry record · Phase 3
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
A Phase 3 study of Type 1 Diabetes, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00206297 is a Phase 3 study of Type 1 Diabetes that has completed, run by Baylor College of Medicine. The registered enrollment target is 20 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00206297, a Phase 3 study of Type 1 Diabetes, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if reducing the dose of insulin before a meal and giving both pramlintide and insulin as dual wave infusions will lower the chance of low blood sugars after a meal. In addition, the study will look at giving pramlintide as a basal infusion (a very low steady dose) for several hours
Conditions Studied
Interventions
- DRUG Pramlintide
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206297
The ClinicalTrials.gov registry entry for NCT00206297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Pramlintide is the first listed.
NCT00206297 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00206297 about?
NCT00206297 is a clinical study titled "The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes". The purpose of this study is to see if reducing the dose of insulin before a meal and giving both pramlintide and insulin as dual wave infusions will lower the chance of low blood sugars after a meal. In addition, the study will look at giving pramlintide as a basal infusion (a very low steady dose)...
What is the current status of trial NCT00206297?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2003-10. Estimated completion is 2006-02.
What conditions does trial NCT00206297 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT00206297?
The interventions under investigation include: Pramlintide (DRUG).
Who is sponsoring clinical trial NCT00206297?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00206297 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
RECRUITING · Phase 3
-
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients
ACTIVE NOT RECRUITING · Phase 3
-
Liraglutide in Adolescents With Type 1 Diabetes
COMPLETED · Phase 3
-
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.